TWI311056B - 6,7-unsaturated-7-carbamoylmorphinan derivatives - Google Patents

6,7-unsaturated-7-carbamoylmorphinan derivatives Download PDF

Info

Publication number
TWI311056B
TWI311056B TW095118443A TW95118443A TWI311056B TW I311056 B TWI311056 B TW I311056B TW 095118443 A TW095118443 A TW 095118443A TW 95118443 A TW95118443 A TW 95118443A TW I311056 B TWI311056 B TW I311056B
Authority
TW
Taiwan
Prior art keywords
group
substituent
substituted
compound
unsubstituted
Prior art date
Application number
TW095118443A
Other languages
English (en)
Chinese (zh)
Other versions
TW200726470A (en
Inventor
Masanao Inagaki
Shin-Ichiro Hara
Nobuhiro Haga
Yoshinori Tamura
Yoshihisa Goto
Tsuyoshi Hasegawa
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of TW200726470A publication Critical patent/TW200726470A/zh
Application granted granted Critical
Publication of TWI311056B publication Critical patent/TWI311056B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095118443A 2005-05-25 2006-05-24 6,7-unsaturated-7-carbamoylmorphinan derivatives TWI311056B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005151864 2005-05-25
JP2006065762 2006-03-10

Publications (2)

Publication Number Publication Date
TW200726470A TW200726470A (en) 2007-07-16
TWI311056B true TWI311056B (en) 2009-06-21

Family

ID=37451954

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095118443A TWI311056B (en) 2005-05-25 2006-05-24 6,7-unsaturated-7-carbamoylmorphinan derivatives

Country Status (20)

Country Link
US (4) USRE46365E1 (cg-RX-API-DMAC10.html)
EP (1) EP1889848B8 (cg-RX-API-DMAC10.html)
JP (1) JP4323547B2 (cg-RX-API-DMAC10.html)
KR (1) KR100912782B1 (cg-RX-API-DMAC10.html)
CN (1) CN101228172B (cg-RX-API-DMAC10.html)
AU (1) AU2006250390B2 (cg-RX-API-DMAC10.html)
BE (1) BE2019C533I2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0610343B8 (cg-RX-API-DMAC10.html)
CA (1) CA2609733C (cg-RX-API-DMAC10.html)
DK (1) DK1889848T3 (cg-RX-API-DMAC10.html)
ES (1) ES2525215T3 (cg-RX-API-DMAC10.html)
FR (1) FR19C1042I2 (cg-RX-API-DMAC10.html)
HU (1) HUS1900034I1 (cg-RX-API-DMAC10.html)
MX (1) MX2007014588A (cg-RX-API-DMAC10.html)
NL (1) NL300996I2 (cg-RX-API-DMAC10.html)
PL (1) PL1889848T3 (cg-RX-API-DMAC10.html)
PT (1) PT1889848E (cg-RX-API-DMAC10.html)
RU (1) RU2403255C2 (cg-RX-API-DMAC10.html)
TW (1) TWI311056B (cg-RX-API-DMAC10.html)
WO (2) WO2006126529A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
WO2009089494A2 (en) * 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
JP5252391B2 (ja) * 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途
AU2009292631A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
CA2774021A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
WO2011142620A2 (en) * 2010-05-13 2011-11-17 Green Cross Corporation (+)-3-hydroxymorphinan-based polycycle derivatives as neuroprotectants
US9108975B2 (en) * 2010-11-12 2015-08-18 Shionogi & Co., Ltd. Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
JP5818219B2 (ja) * 2012-05-14 2015-11-18 塩野義製薬株式会社 ６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
US11135217B2 (en) 2016-12-26 2021-10-05 Shionogi & Co., Ltd. Manufacturing process of formulation having improved content uniformity
EP3773573A4 (en) 2018-04-12 2022-04-06 Morphic Therapeutic, Inc. ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7)
KR102201609B1 (ko) 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
RS66976B1 (sr) 2019-10-16 2025-07-31 Morphic Therapeutic Inc Inhibiranje ljudskog integrina alfa4beta7
JP7582961B2 (ja) 2019-11-20 2024-11-13 塩野義製薬株式会社 ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤
CN111905111B (zh) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法
IT202300009864A1 (it) * 2023-05-16 2024-11-16 Procos Spa Processo per la preparazione di naldemedina

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4275205A (en) 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4443605A (en) 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
US4440932A (en) 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
CA2143864C (en) 1993-07-23 2006-01-24 Hiroshi Nagase Morphinan derivatives and pharmaceutical use thereof
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
TR199801348T2 (xx) 1996-01-10 1998-10-21 Smithkline Beecham S.P.A. Heterosikl-kondanse morfinoid t�revleri(II).
WO2001002375A1 (en) 1999-07-01 2001-01-11 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
AU784541B2 (en) 1999-11-29 2006-04-27 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
CA2408106A1 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
AU2001259560B2 (en) * 2000-05-05 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
EP1353909B1 (en) * 2000-10-31 2005-04-06 Rensselaer Polytechnic Institute 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioidreceptor binding agents
WO2002042309A1 (en) * 2000-11-22 2002-05-30 Toray Industries, Inc. Indole derivatives and use thereof in medicines
PL368732A1 (en) * 2001-08-23 2005-04-04 Akzo Nobel N.V. C-14 oxidation of morphine derivatives
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
WO2004007503A1 (ja) * 2002-07-11 2004-01-22 Toray Industries, Inc. 悪心・嘔吐の治療または予防剤
EP1539767A4 (en) 2002-09-18 2006-07-19 Univ Missouri FOR THE DELTA OPIOID RECEPTOR SELECTIVE OPIATANALOGA
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
US8481501B2 (en) 2004-05-28 2013-07-09 Human Biomolecular Research Institute Synthesis of metabolically stable analgesics, pain medications and other agents
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US7142420B2 (en) 2004-09-20 2006-11-28 Qualcomm, Incorporated Devices and methods for controlling relative movement between layers of an electronic device
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
US9108975B2 (en) 2010-11-12 2015-08-18 Shionogi & Co., Ltd. Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same

Also Published As

Publication number Publication date
PL1889848T3 (pl) 2015-04-30
JPWO2006126637A1 (ja) 2008-12-25
AU2006250390A1 (en) 2006-11-30
EP1889848B1 (en) 2014-10-15
US20120135978A1 (en) 2012-05-31
USRE46365E1 (en) 2017-04-11
US8084460B2 (en) 2011-12-27
CA2609733A1 (en) 2006-11-30
FR19C1042I1 (cg-RX-API-DMAC10.html) 2019-08-09
RU2007148412A (ru) 2009-06-27
JP4323547B2 (ja) 2009-09-02
US8536192B2 (en) 2013-09-17
RU2403255C2 (ru) 2010-11-10
CN101228172A (zh) 2008-07-23
BRPI0610343B1 (pt) 2020-03-10
NL300996I1 (nl) 2019-07-03
PT1889848E (pt) 2014-12-09
US20090203723A1 (en) 2009-08-13
WO2006126529A1 (ja) 2006-11-30
FR19C1042I2 (fr) 2020-06-19
DK1889848T3 (en) 2014-12-01
EP1889848A4 (en) 2011-08-10
USRE46375E1 (en) 2017-04-25
EP1889848B8 (en) 2014-12-17
BRPI0610343A2 (pt) 2010-06-15
CN101228172B (zh) 2013-04-03
EP1889848A1 (en) 2008-02-20
CA2609733C (en) 2011-07-19
BE2019C533I2 (cg-RX-API-DMAC10.html) 2025-12-10
HUS1900034I1 (hu) 2019-07-29
KR100912782B1 (ko) 2009-08-18
WO2006126637A1 (ja) 2006-11-30
ES2525215T3 (es) 2014-12-19
AU2006250390B2 (en) 2010-07-08
MX2007014588A (es) 2008-01-24
TW200726470A (en) 2007-07-16
NL300996I2 (nl) 2019-07-30
KR20080014791A (ko) 2008-02-14
BRPI0610343B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
TWI311056B (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
DE69321525T2 (de) Morphinan-derivate und medizinische verwendung
WO2020216190A1 (zh) 一种喹唑啉化合物及其在医药上的应用
US6187782B1 (en) Morphinane derivatives and medicinal use thereof
EP3610874A1 (en) Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof
WO2007067994A1 (en) Inhibitors of histone deacetylase for the treatment of disease
WO2007084868A2 (en) Treatment of disorders by activation of the unfolded protein response
WO2007011760A2 (en) Inhibitors of mitotic kinesin
WO2020042995A1 (zh) 一种高活性sting蛋白激动剂化合物
WO2019109937A1 (zh) Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途
WO2008001859A1 (fr) AGONISTE DES RÉCEPTEURS δ DES OPIOÏDES
TWI690512B (zh) 對位取代的不對稱脲及其醫療用途
CN116354933A (zh) 作为雄激素受体调节剂的杂环化合物及其应用
WO2007011759A2 (en) Inhibitors of mitotic kinesin
TW201418251A (zh) 經環狀脲或內醯胺取代之喹□啉型哌啶化合物及其用途
JP2016540793A (ja) 疼痛に対して多重モードの活性を有するピペリジン化合物
EP1959967A2 (en) Inhibitors of histone deacetylase for the treatment of disease
WO2024197429A1 (zh) 作为雄激素受体调节剂的杂环化合物及其应用
CN114980886B (zh) 用于治疗草酸盐相关疾病的化合物和方法
WO2007011721A1 (en) Inhibitors of mitotic kinesin
EP3269721B1 (en) Bicyclic pyridine compound
TW202340170A (zh) -2-基)-1h-吲哚-7-甲腈之結晶形式
WO2007055184A1 (ja) 機能性腸障害の治療または予防剤
WO2007011647A2 (en) Inhibitors of mitotic kinesin ksp
TW201627301A (zh) 具有抗疼痛之多重模式活性的哌啶化合物